Table 1 Association between the expression of YWHAG protein and clinicopathological features of LUAD (n = 133)
From: YWHAG promotes the progression of lung adenocarcinoma through the JAK2/STAT3 pathway
Variables | YWHAG | ||
|---|---|---|---|
Low expression | High expression | P | |
Age (years) | |||
<56 (n = 49) | 34 (69.4%) | 15 (30.6%) | 0.204 |
≥56 (n = 84) | 49 (58.3%) | 35 (41.7%) | |
Gender | |||
Female (n = 55) | 38 (69.1%) | 17 (30.9%) | 0.181 |
Male (n = 78) | 45 (57.7%) | 33 (42.3%) | |
Pathological grade | |||
Well/moderate (n = 63) | 45 (71.4%) | 18 (28.6%) | 0.042* |
Poor (n = 70) | 38 (54.3%) | 32 (45.7%) | |
Clinical stage | |||
Stage I and II (n = 67) | 44 (65.7%) | 23 (34.3%) | 0.433 |
Stage III (n = 66) | 39 (59.1%) | 27 (40.9%) | |
LNM status | |||
LNM (n = 78) | 43 (55.1%) | 35 (44.9%) | 0.039* |
No LNM (n = 55) | 40 (72.7%) | 15 (27.3%) | |